# Feasibility and Efficacy of Modified Donor Lymphocytes Infusion (CD45RA Negative Selected) After Haploidentical Transplantation With Post-transplantation Cyclophosphamide in Patients With Hematological Malignancies (ONC-2016-002).

> **NCT04687982** · NA · COMPLETED · sponsor: **Istituto Clinico Humanitas** · enrollment: 19 (actual)

## Conditions studied

- Bone Marrow Transplant Infection
- Bone Marrow Transplant Complications
- Graft Vs Host Disease
- Infection
- Hematological Malignancy

## Interventions

- **BIOLOGICAL:** modified donor lymphocytes infusion (mDLI)

## Key facts

- **NCT ID:** NCT04687982
- **Lead sponsor:** Istituto Clinico Humanitas
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-13
- **Primary completion:** 2020-01-08
- **Final completion:** 2020-01-08
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2020-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04687982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04687982, "Feasibility and Efficacy of Modified Donor Lymphocytes Infusion (CD45RA Negative Selected) After Haploidentical Transplantation With Post-transplantation Cyclophosphamide in Patients With Hematological Malignancies (ONC-2016-002).". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04687982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*